26 results
Keyword Alemtuzumab Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Lemtrada (updated)
alemtuzumab, Multiple Sclerosis
Date of authorisation: 12/09/2013,
, 
, Revision: 11, Authorised, Last updated: 25/03/2021
Authorised alemtuzumab Overview Lemtrada is a medicine … contains the active substance alemtuzumab. How is Lemtrada used? Lemtrada … active substance in Lemtrada, alemtuzumab, is a type of protein called … -
List item
Human medicine European public assessment report (EPAR): MabCampath
alemtuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 06/07/2001, Revision: 14, Withdrawn, Last updated: 15/08/2012Withdrawn alemtuzumab Overview The marketing authorisation … statement on MabCampath (alemtuzumab): Withdrawal of the marketing … statement on MabCampath (alemtuzumab): Withdrawal of the marketing … -
List item
Human medicine European public assessment report (EPAR): Arzerra
ofatumumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 19/04/2010, Revision: 16, Withdrawn, Last updated: 10/05/2019refractory to fludarabine and alemtuzumab. Clinical data (variation … refractory to fludarabine and alemtuzumab: summary of the scientific … -
List item
Human medicine European public assessment report (EPAR): Gamifant (updated)
Emapalumab, Immune System Diseases
Date of refusal: 07/01/2021,
, Refused, Last updated: 23/03/2021
-
List item
Human medicine European public assessment report (EPAR): Tysabri (updated)
natalizumab, Multiple Sclerosis
Date of authorisation: 27/06/2006, Revision: 33, Authorised, Last updated: 06/04/2021 -
List item
Human medicine European public assessment report (EPAR): Gilenya
fingolimod hydrochloride , Multiple Sclerosis
Date of authorisation: 17/03/2011,, , Revision: 28, Authorised, Last updated: 04/02/2021
-
List item
Human medicine European public assessment report (EPAR): Ocrevus (updated)
ocrelizumab, Multiple Sclerosis
Date of authorisation: 08/01/2018,, Revision: 10, Authorised, Last updated: 29/03/2021
-
List item
Human medicine European public assessment report (EPAR): Mayzent
Siponimod fumaric acid, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 13/01/2020,, Revision: 4, Authorised, Last updated: 14/01/2021
-
List item
Human medicine European public assessment report (EPAR): Imbruvica
Ibrutinib, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 21/10/2014,, Revision: 21, Authorised, Last updated: 26/02/2021
-
List item
Human medicine European public assessment report (EPAR): Prevymis
Letermovir, Cytomegalovirus Infections
Date of authorisation: 08/01/2018,, , Revision: 8, Authorised, Last updated: 01/02/2021
-
List item
Human medicine European public assessment report (EPAR): Zeposia
ozanimod hydrochloride, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 20/05/2020,, Authorised, Last updated: 26/10/2020
-
List item
Human medicine European public assessment report (EPAR): Gazyvaro
Obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 22/07/2014,, , Revision: 11, Authorised, Last updated: 29/01/2021
-
List item
Human medicine European public assessment report (EPAR): Mavenclad
Cladribine, Multiple Sclerosis
Date of authorisation: 22/08/2017, Revision: 3, Authorised, Last updated: 04/03/2020 -
List item
Human medicine European public assessment report (EPAR): Zessly
infliximab, Arthritis, Psoriatic, Psoriasis, Crohn Disease, Arthritis, Rheumatoid, Colitis, Ulcerative, Spondylitis, Ankylosing
Date of authorisation: 18/05/2018,, 
, Revision: 6, Authorised, Last updated: 11/11/2020
-
List item
Human medicine European public assessment report (EPAR): Revolade
Eltrombopag, Purpura, Thrombocytopenic, Idiopathic
Date of authorisation: 11/03/2010, Revision: 26, Authorised, Last updated: 25/02/2021 -
List item
Human medicine European public assessment report (EPAR): Erelzi
etanercept, Arthritis, Psoriatic, Psoriasis, Arthritis, Juvenile Rheumatoid, Arthritis, Rheumatoid, Spondylitis, Ankylosing
Date of authorisation: 23/06/2017,, , Revision: 8, Authorised, Last updated: 04/01/2021
-
List item
Human medicine European public assessment report (EPAR): Tecfidera
dimethyl fumarate, Multiple Sclerosis
Date of authorisation: 30/01/2014, Revision: 20, Authorised, Last updated: 11/12/2020 -
List item
Human medicine European public assessment report (EPAR): Zydelig
Idelalisib, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 18/09/2014,, Revision: 17, Authorised, Last updated: 05/11/2020
-
List item
Human medicine European public assessment report (EPAR): Plegridy
peginterferon beta-1a, Multiple Sclerosis
Date of authorisation: 17/07/2014, Revision: 21, Authorised, Last updated: 11/03/2021 -
List item
Human medicine European public assessment report (EPAR): Cosentyx (updated)
Secukinumab, Arthritis, Psoriatic, Psoriasis, Spondylitis, Ankylosing
Date of authorisation: 14/01/2015, Revision: 20, Authorised, Last updated: 25/03/2021 -
List item
Human medicine European public assessment report (EPAR): Venclyxto
Venetoclax, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 04/12/2016,, Revision: 10, Authorised, Last updated: 07/05/2020
-
List item
Human medicine European public assessment report (EPAR): Torisel
Temsirolimus, Carcinoma, Renal Cell, Lymphoma, Mantle-Cell
Date of authorisation: 19/11/2007, Revision: 30, Authorised, Last updated: 06/11/2020 -
List item
Human medicine European public assessment report (EPAR): Folotyn
Pralatrexate, Lymphoma, T-Cell
Date of refusal: 21/06/2012,, Refused, Last updated: 11/07/2012
-
List item
Human medicine European public assessment report (EPAR): Istodax
romidepsin, Lymphoma, Non-Hodgkin
Date of refusal: 12/02/2013,, Refused, Last updated: 14/03/2013
-
List item
Human medicine European public assessment report (EPAR): Zinbryta
daclizumab, Multiple Sclerosis
Date of authorisation: 01/07/2016,, Revision: 8, Withdrawn, Last updated: 28/06/2018